BiotechTV

•

Channel • 5 Shows

Life Sciences

Life Sciences

Updated 5d ago
Life Sciences

Life Sciences

Updated Biweekly
Life Sciences

Life Sciences

Updated Apr 16
Life Sciences

Life Sciences

Updated Sep 3
Life Sciences

Life Sciences

Updated Jun 25

5d ago

Eli Lilly Chairman & CEO David Ricks discusses GLP-1's, Alzheimer's, business development and more

From the company's headquarters in Indianapolis, he describes where he thinks the obesity field could be headed in the next few years, what might be next after beta-amyloid in Alzheimer's, and how he plans to invest for the future.
Oct 5

Episode 49: Sanofi Ventures' Jason Hafler

Jason Hafler shares an overview of the corporate side of the venture world. He describes the unique value that he believes a corporate based VC can bring to the companies it invests in. Plus, his description of cases where investments might ultimately be a good fit for BD and/or M&A within the company, and why an investment might ultimately land at a different suitor.
Oct 5

After a busy time in Boston during the Aging Research and Drug Discovery Meeting, Insilico Medicine CEO Alex Zhavoronkov discusses the latest in longevity therapeutics and Insilico's pipeline progress

He describes the biomarkers that researchers and investigators have been using, and how large pharma companies like Lilly and Novo Nordisk have begun to embrace the field. Plus, the logevity component Insilico has built into its IPF trials, and what other programs and targets he calls out.
Sep 21

Episode 48: Blackstone's Kiran Reddy

Blackstone's Senior Managing Director Kiran Reddy describes his early life and education, and the impact that patient care has had on his approach to investing. He describes notable investments in neuroscience, and a stop at Biogen, before returning to investing at Clarus, which was acquired by Blackstone. He recalls the unique opportunity he saw when a company with the resources of Blackstone decided to go big into life sciences.
09/22/2025

Episode 25: Atlas Venture's Bruce Booth

Bruce Booth discusses his education and early career, the structure of Atlas and the types of investments it makes, investing in assets vs platforms, and more.
Oct 2

Monte Rosa Therapeutics announced data for MRT-8102, its NEK7-directed molecular glue degrader, showing positive impact on biomarkers linked to atherosclerotic cardiovascular disease

CEO Markus Warmuth walks us through the data and provides a broader update on the pipeline progress at Monte Rosa and for the field of degraders and molecular glues more broadly.
Jul 27

Episode 44: BainCapital's Adam Koppel

Adam Koppel describes his career path, which included a stop at McKinsey, Biogen, and twice at Bain (where he is now). He descrbies the private equity model they have been on the leading edge of, and his take on where we are in the biotech cycle. Plus, the critical importance of mentors.
Jun 25

Episode 7: Perceptive Advisors' Joe Edelman discusses how biotech investing has changed over his extensive career, and his thoughts on running an investment firm

He describes to Matt how the market has become more efficient since he started in the 1990's. He shares his perspective on single-asset vs pipeline companies, and today's M&A dynamic. Plus, his goal of being unbiased as an investor and how he tries to create an environment at Perceptive where that style is instilled in his analysts.
Aug 10

Episode 45: Catalio Capital Management's George Petrocheilos

George Petrocheilos describes going to school at Hopkins and the relationships formed there that would ultimately lead down the road to specializing in healthcare investing. He discusses starting in life sciences investing at Camden Partners, and then co-founding Catalio. Over a short period of time, keys to success have been empowering academics and entrepreneurs and expanding into multiple strategies.
Apr 23

Episode 6: BridgeBio Founder & CEO Neil Kumar discusses the hub and spoke biotech model and trying to build a sustainable business for the long-term

He and Matt talk about portfolio construction, and the dynamics of taking on the right capital structure throughout different phases of a company's lifecycle. Neil shares early learnings from the commercial launch of Attruby, how being a commercial stage company can impact culture, and why he created the early-stage R&D focused sister company Gondola. Plus, discussing talent, intellectual property, and more.

BiotechTV covers the biotechnology sector through news, stories, podcasts, and educational videos.

Website

BiotechTV

Top Shows

Eli Lilly Chairman & CEO David Ricks discusses GLP-1's, Alzheimer's, business development and more

Episode 49: Sanofi Ventures' Jason Hafler

After a busy time in Boston during the Aging Research and Drug Discovery Meeting, Insilico Medicine CEO Alex Zhavoronkov discusses the latest in longevity therapeutics and Insilico's pipeline progress

Episode 48: Blackstone's Kiran Reddy

Episode 25: Atlas Venture's Bruce Booth

Monte Rosa Therapeutics announced data for MRT-8102, its NEK7-directed molecular glue degrader, showing positive impact on biomarkers linked to atherosclerotic cardiovascular disease

Episode 44: BainCapital's Adam Koppel

Episode 7: Perceptive Advisors' Joe Edelman discusses how biotech investing has changed over his extensive career, and his thoughts on running an investment firm

Episode 45: Catalio Capital Management's George Petrocheilos

Episode 6: BridgeBio Founder & CEO Neil Kumar discusses the hub and spoke biotech model and trying to build a sustainable business for the long-term

About

BiotechTV

Top Shows

Top Episodes

About